Search for a trial

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of
Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or
Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2023-503715-14-00 check the CTIS register for the current data. Part A: To characterize the safety, tolerability, and define the MTD or RP2D for the combination of relatlimab + nivolumab in pediatric…

CHIP-AML22/Quizartinib: A phase II, single arm, open label, study on the safety, efficacy, pharmacokinetics and pharmacodynamics of quizartinib in combination with chemotherapy and as single-agent after high dose therapy in newly diagnosed pediatric FLT3-ITD positive and NPM1 wild type AML patients.
(A linked-trial of the CHIP-AML22/Master protocol by the NOPHO-DB-SHIP consortium)

This study has been transitioned to CTIS with ID 2023-505000-27-01 check the CTIS register for the current data. To investigate the safety and efficacy of quizartinib in children and adolescents with newly diagnosed FLT3-ITD positive AML with normal…

Online CBT for bereaved youth due to a traffic accident

The primary aim of the current study is to evaluate the potential effectiveness of online grief-specific CBT, in terms of reductions in symptom-levels of PGD, PTSD, and depression, for children and adolescents who lost a loved one due to a traffic…

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children. Sub-Protocol D: Trametinib + Dexamethasone
+ Cyclophosphamide and Cytarabine in pediatric patients with relapsed or refractory hematological malignancies

This study has been transitioned to CTIS with ID 2022-501869-41-00 check the CTIS register for the current data. PrimaryPhase I: To assess the safety and tolerability of the investigational agents and define the MTD/RP2D(s)Phase II: To evaluate the…

The effectiveness of a virtual reality intervention on trauma-related shame in sexually abused adolescents: A single-case experimental study.

The goal of this study is to test the effectiveness of a short-term VR shame intervention (SHINE-VR) for adolescents suffering from PTSD after having experienced sexual abuse. The primary objectives of this study are:1) To assess the effect of SHINE…

An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder

This study has been transitioned to CTIS with ID 2023-510007-22-00 check the CTIS register for the current data. NMOSD is associated with a high degree of disability and mortality, and there is a unmet medical need in children with this disease.…

Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I)

The hypothesis is that personalised and risk-adapted treatment will improve outcome and reduce toxicity in post-pubertal patients with medulloblastoma.A further hypothesis is that clinical, magnetic resonance imaging (MRI) and voxel-based…

A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy

This study has been transitioned to CTIS with ID 2023-509710-11-00 check the CTIS register for the current data. Study Objectives:The purpose of this Phase 2 study is to evaluate the safety, efficacy, pharmacokinetics (PK),pharmacodynamics (PD), and…

Treatment study for children and adolescents with Acute Promyelocytic Leukemia

This study has been transitioned to CTIS with ID 2024-518669-83-00 check the CTIS register for the current data. Primary objective:To assess, in an international pediatric study, the efficacy, in terms of event-free survival, of a combination of ATO…

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

This study has been transitioned to CTIS with ID 2024-514266-39-00 check the CTIS register for the current data. Phase 1 Primary Objective(s):-to evaluate the overall safety and tolerability of NVL-655-to determine the RP2D and, if applicable, the…